Cardinal Health, Inc. CAH is scheduled to report fiscal second-quarter 2025 results on Jan. 30, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 14.

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

Cardinal Health CEO Jason Hollar recounted the company's "nice run" at the nation's largest annual healthcare industry conference. Cardinal Health Inc. raised its earnings outlook for fiscal 2025 ...

Drug distributor Cardinal Health said on Thursday it may need to increase prices of some of its products if the proposed tariffs on Mexico go into effect, to counter increasing costs of manufacturing ...

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

Argus analyst Kristina Ruggeri raised the firm’s price target on Cardinal Health (CAH) to $148 from $145 and keeps a Buy rating on the shares.

Headquartered in Columbus, Ohio, Cardinal Health is a global, integrated healthcare services and products company that generated $205 billion in revenue in its fiscal year 2023. The company plays ...